US 11,674,169 B2
Isolation of nucleic acids
Janelle J. Bruinsma, Madison, WI (US); Michael J. Domanico, Middleton, WI (US); Graham P. Lidgard, Madison, WI (US); Hongzhi Zou, Middleton, WI (US); William G. Weisburg, San Diego, CA (US); Hemanth D. Shenoi, Verona, WI (US); James P. Light, II, Middleton, WI (US); Keith Kopitzke, Fallbrook, CA (US); and John Zeis, San Marcos, CA (US)
Assigned to Exact Sciences Corporation, Madison, WI (US)
Filed by Exact Sciences Corporation, Madison, WI (US)
Filed on Sep. 29, 2020, as Appl. No. 17/35,822.
Application 17/035,822 is a continuation of application No. 16/212,143, filed on Dec. 6, 2018, granted, now 10,822,639.
Application 16/212,143 is a continuation of application No. 16/046,669, filed on Jul. 26, 2018, granted, now 10,196,676, issued on Feb. 5, 2019.
Application 16/046,669 is a continuation of application No. 15/807,970, filed on Nov. 9, 2017, granted, now 10,047,390, issued on Aug. 14, 2018.
Application 15/807,970 is a continuation of application No. 14/939,925, filed on Nov. 12, 2015, granted, now 9,845,491, issued on Dec. 19, 2017.
Application 14/939,925 is a continuation of application No. 14/713,289, filed on May 15, 2015, granted, now 9,631,228, issued on Apr. 25, 2017.
Application 14/713,289 is a continuation of application No. 14/145,082, filed on Dec. 31, 2013, granted, now 9,163,278, issued on Oct. 20, 2015.
Application 14/145,082 is a continuation of application No. PCT/US2012/037581, filed on May 11, 2012.
Claims priority of provisional application 61/485,448, filed on May 12, 2011.
Claims priority of provisional application 61/485,386, filed on May 12, 2011.
Claims priority of provisional application 61/485,214, filed on May 12, 2011.
Claims priority of provisional application 61/485,338, filed on May 12, 2011.
Prior Publication US 2021/0017577 A1, Jan. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6806 (2018.01); B03C 1/30 (2006.01); B01D 33/15 (2006.01); B01L 3/00 (2006.01); C12N 15/10 (2006.01); B04B 3/00 (2006.01); C12Q 1/6886 (2018.01)
CPC C12Q 1/6806 (2013.01) [B01D 33/15 (2013.01); B01D 33/155 (2013.01); B01L 3/00 (2013.01); B01L 3/5021 (2013.01); B03C 1/30 (2013.01); B04B 3/00 (2013.01); C12N 15/1006 (2013.01); C12N 15/1013 (2013.01); C12N 15/1017 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); Y10T 436/143333 (2015.01)] 11 Claims
OG exemplary drawing
 
1. A method for partitioning a human stool homogenate comprising human DNA and bacterial DNA to produce a human target DNA preparation and a residual supernatant, the method comprising:
a) treating a fluid fraction from a human stool homogenate with insoluble polyvinylpyrrolidone to bind inhibitor, if present, in an insoluble inhibitor complex, to produce a treated stool fluid;
b) exposing the treated stool fluid to a target sequence-specific capture reagent comprising particles attached to oligonucleotides complementary to at least a portion of first human target DNAs under conditions wherein the first target sequence-specific capture reagent forms first capture complexes comprising the target sequence-specific capture reagent and the first human target DNAs;
c) separating the first capture complexes from the treated stool fluid to produce:
i) a human target DNA preparation comprising the first human target DNAs captured in first capture complexes in step b); and
ii) a residual supernatant comprising bacterial DNA and human target DNAs not complementary to the oligonucleotides of the target-sequence specific capture reagent used in step b).